<DOC>
	<DOCNO>NCT00359944</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety different dos AC-3933 patient mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>Safety Efficacy Study AC-3933 Adults With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mild moderate Alzheimer 's Disease Male female 55 year old Living caregiver Read , understand speak English Need drive study Treatment acetylcholinesterase inhibitor NMDA antagonist , Aricept Namenda , within 2 week checkup study Frequent Smoker Frequent Consumer Caffeine</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>Dementia</keyword>
</DOC>